304 related articles for article (PubMed ID: 19041620)
1. Pharmaceutical new product development: the increasing role of in-licensing.
Edwards NV
Anesthesiol Clin; 2008 Dec; 26(4):627-36, v. PubMed ID: 19041620
[TBL] [Abstract][Full Text] [Related]
2. Pharmaceutical technology management--profitable business avenue.
Puthli SP
Expert Opin Drug Deliv; 2010 Jan; 7(1):1-5. PubMed ID: 20017657
[TBL] [Abstract][Full Text] [Related]
3. The interaction between intellectual property and drug regulatory systems: global perspectives.
Madden EA
IDrugs; 2007 Feb; 10(2):116-20. PubMed ID: 17285464
[TBL] [Abstract][Full Text] [Related]
4. Ownership of knowledge--the role of patents in pharmaceutical R&D.
Correa CM
Bull World Health Organ; 2004 Oct; 82(10):784-7; discussion 787-90. PubMed ID: 15643801
[TBL] [Abstract][Full Text] [Related]
5. [Intellectual property rights and right of access to medicines].
Velásquez G
Med Trop (Mars); 2006 Dec; 66(6):526-8. PubMed ID: 17286013
[TBL] [Abstract][Full Text] [Related]
6. [Exclusivity of data in drug registration files and Israel's international status with regard to intellectual property rights protection].
Lipschitz Y; Tamir O; Shemer J
Harefuah; 2004 Dec; 143(12):845-8, 912. PubMed ID: 15666700
[TBL] [Abstract][Full Text] [Related]
7. Selection of licensing candidates in the pharmaceutical industry: an application of the analytic hierarchy process.
Ross ME; Nydick RL
J Health Care Mark; 1992 Jun; 12(2):60-5. PubMed ID: 10119215
[TBL] [Abstract][Full Text] [Related]
8. Brazil: An emerging partner in drug R&D.
Rodrigues DG
IDrugs; 2009 Aug; 12(8):497-502. PubMed ID: 19629884
[TBL] [Abstract][Full Text] [Related]
9. Pharmaceutical pipeline.
Lowen T
Minn Med; 2011 Oct; 94(10):16-8. PubMed ID: 23256279
[No Abstract] [Full Text] [Related]
10. Innovation strategies for generic drug companies: moving into supergenerics.
Ross MS
IDrugs; 2010 Apr; 13(4):243-7. PubMed ID: 20373253
[TBL] [Abstract][Full Text] [Related]
11. Ovation Pharmaceuticals, Inc.
Deutsch B
Pharmacogenomics; 2002 Nov; 3(6):839-41. PubMed ID: 12437486
[TBL] [Abstract][Full Text] [Related]
12. Does brand differentiate pharmaceuticals?
Bednarik J
Neuro Endocrinol Lett; 2005 Dec; 26(6):635-52. PubMed ID: 16380705
[TBL] [Abstract][Full Text] [Related]
13. [Industry and pharmaceutical research in Italy. How to make up for lost time].
Mortari U
Recenti Prog Med; 2006 Nov; 97(11):634-9. PubMed ID: 17252720
[TBL] [Abstract][Full Text] [Related]
14. Licensing: pros and cons for biotech.
Villiger R; Bogdan B
Drug Discov Today; 2009 Mar; 14(5-6):227-30. PubMed ID: 19200456
[TBL] [Abstract][Full Text] [Related]
15. Intellectual property rights, compulsory licensing and the TRIPS agreement: some ethical issues.
Schuklenk U
Monash Bioeth Rev; 2003 Apr; 22(2):63-8. PubMed ID: 15069958
[No Abstract] [Full Text] [Related]
16. Overcoming the obstacles in the pharma/biotech industry: 2008 update.
Graul AI; Revel L; Rosa E; Cruces E
Drug News Perspect; 2009; 22(1):39-51. PubMed ID: 19209298
[TBL] [Abstract][Full Text] [Related]
17. Effective executive management in the pharmaceutical industry.
Tran H; Kleiner BH
J Health Care Finance; 2005; 32(1):8-15. PubMed ID: 18972973
[TBL] [Abstract][Full Text] [Related]
18. Examining the applicability of market forecasting models to new pharmaceutical products.
Agrawal M; Calantone RJ
Health Mark Q; 1996; 13(4):17-31. PubMed ID: 10159642
[TBL] [Abstract][Full Text] [Related]
19. Sponsored research agreements, university and government licensing, and clinical trial agreements: special contractual and intellectual property rights considerations.
Somers JP
J Biolaw Bus; 2003; 6(4):5-13. PubMed ID: 15072054
[TBL] [Abstract][Full Text] [Related]
20. Market-based licensing for HPV vaccines in developing countries.
Outterson K; Kesselheim AS
Health Aff (Millwood); 2008; 27(1):130-9. PubMed ID: 18180488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
